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Summary
Each year, the American Heart Association (AHA), in con-
junction with the Centers for Disease Control and Prevention, 
the National Institutes of Health, and other government agen-
cies, brings together the most up-to-date statistics on heart 
disease, stroke, other vascular diseases, and their risk factors 
and presents them in its Heart Disease and Stroke Statisti-
cal Update . The Statistical Update is a valuable resource for 
researchers, clinicians, healthcare policy makers, media pro-
fessionals, the lay public, and many others who seek the best 
national data available on heart disease, stroke, and other car-
diovascular disease–related morbidity and mortality and the 
risks, quality of care, medical procedures and operations, and 
costs associated with the management of these diseases in a 
single document . Indeed, since 1999, the Statistical Update 
has been cited >10 500 times in the literature, based on cita-
tions of all annual versions . In 2011 alone, the various Statis-
tical Updates were cited ≈1500 times (data from ISI Web of 
Science) . In recent years, the Statistical Update has undergone 
some major changes with the addition of new chapters and 
major updates across multiple areas, as well as increasing the 
number of ways to access and use the information assembled .
For this year’s edition, the Statistics Committee, which pro-
duces the document for the AHA, updated all of the current 
chapters with the most recent nationally representative data and 
inclusion of relevant articles from the literature over the past year . 
This year’s edition also implements a new chapter organization to 
reflect the spectrum of cardiovascular health behaviors and health 
factors and risks, as well as subsequent complicating conditions, 
disease states, and outcomes . Also, the 2013 Statistical Update 
contains new data on the monitoring and benefits of cardiovas-
cular health in the population, with additional new focus on evi-
dence-based approaches to changing behaviors, implementation 
strategies, and implications of the AHA’s 2020 Impact Goals . 
Below are a few highlights from this year’s Update .
The 2013 Update Expands Data Coverage of the 
Epidemic of Poor Cardiovascular Health Behaviors 
and Their Antecedents and Consequences
●● Adjusted population attributable fractions for cardiovascular 
disease (CVD) mortality were as follows1: 40 .6% (95% confi-
dence interval [CI], 24 .5–54 .6) for high blood pressure; 13 .7% 
(95% CI, 4 .8–22 .3) for smoking; 13 .2% (95% CI, 3 .5–29 .2) 
for poor diet; 11 .9% (95% CI, 1 .3–22 .3) for insufficient physi-
cal activity; and 8 .8% (95% CI, 2 .1–15 .4) for abnormal glu-
cose levels .
●● Despite 4 decades of progress, in 2011, among Americans 
≥18 years of age, 21 .3% of men and 16 .7% of women con-
tinued to be cigarette smokers . In 2011, 18 .1% of students 
in grades 9 through 12 reported current cigarette use .
●● The percentage of the nonsmoking population with detect-
able serum cotinine (indicating exposure to secondhand 
smoke) declined from 52 .5% in 1999 to 2000 to 40 .1% in 
2007 to 2008, with declines higher for those 3 to 11 years 
of age (–53 .6%) and those 12 to 19 years of age (–46 .5%) 
than for those 20 years of age and older (–36 .7%) .
●● The proportion of youth (≤18 years of age) who report engag-
ing in no regular physical activity is high, and the proportion 
increases with age . In 2011, among adolescents in grades 9 
through 12, 17 .7% of girls and 10 .0% of boys reported that 
they had not engaged in ≥60 minutes of moderate-to-vigor-
ous physical activity, defined as any activity that increased 
heart rate or breathing rate, even once in the previous 7 days, 
despite recommendations that children engage in such activity 
7 days per week .
●● Thirty two percent of adults reported engaging in no aero-
bic leisure-time physical activity .
●● Data from the National Health and Nutrition Examination 
Survey (NHANES) indicate that between 1971 and 2004, 
average total energy consumption among US adults increased 
by 22% in women (from 1542 to 1886 kcal/d) and by 10% in 
men (from 2450 to 2693 kcal/d) .
●● The increases in calories consumed during this time period are 
attributable primarily to greater average carbohydrate intake, 
in particular, of starches, refined grains, and sugars . Other spe-
cific changes related to increased caloric intake in the United 
States include larger portion sizes, greater food quantity and 
calories per meal, and increased consumption of sugar-sweet-
ened beverages, snacks, commercially prepared (especially 
fast food) meals, and higher energy-density foods .
●● The estimated prevalence of overweight and obesity in US 
adults (≥20 years of age) is 154 .7 million, which represents 
68 .2% of this group in 2010 . Fully 34 .6% of US adults are 
obese (body mass index ≥30 kg/m2) . Men and women of all 
race/ethnic groups in the population are affected by the epi-
demic of overweight and obesity .
●● Among children 2 to 19 years of age, 31 .8% are over-
weight and obese (which represents 23 .9 million children) 
and 16 .9% are obese (12 .7 million children) . Mexican 
American boys and girls and African American girls are 
disproportionately affected . Over the past 3 decades, the 
prevalence of obesity in children 6 to 11 years of age has 
increased from ≈4% to >20% .
●● Obesity (body mass index ≥30 kg/m2) is associated with 
marked excess mortality in the US population . Even more 
notable is the excess morbidity associated with overweight 
and obesity in terms of risk factor development and 
incidence of diabetes mellitus, CVD end points (including 
coronary heart disease, stroke, and heart failure), and 
numerous other health conditions, including asthma, 
cancer, end-stage renal disease, degenerative joint disease, 
and many others .
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Prevalence and Control of Cardiovascular Health 
Factors and Risks Remains an Issue for Many 
Americans
●● An estimated 31 .9 million adults ≥20 years of age have 
total serum cholesterol levels ≥240 mg/dL, with a preva-
lence of 13 .8% .
●● Based on 2007 to 2010 data, 33 .0% of US adults ≥20 years 
of age have hypertension . This represents 78 million US 
adults with hypertension . The prevalence of hypertension is 
nearly equal between men and women . African American 
adults have among the highest prevalence of hypertension 
(44%) in the world .
●● Among hypertensive adults, ≈82% are aware of their con-
dition and 75% are using antihypertensive medication, but 
only 53% of those with documented hypertension have their 
condition controlled to target levels .
●● In 2010, an estimated 19 .7 million Americans had diagnosed 
diabetes mellitus, representing 8 .3% of the adult population . 
An additional 8 .2 million had undiagnosed diabetes mellitus, 
and 38 .2% had prediabetes, with abnormal fasting glucose 
levels . African Americans, Mexican Americans, Hispanic/
Latino individuals, and other ethnic minorities bear a strik-
ingly disproportionate burden of diabetes mellitus in the 
United States .
●● The prevalence of diabetes mellitus is increasing dramati-
cally over time, in parallel with the increases in prevalence 
of overweight and obesity .
●● On the basis of NHANES 2003–2006 data, the age-adjusted 
prevalence of metabolic syndrome, a cluster of major car-
diovascular risk factors related to overweight/obesity and 
insulin resistance, is ≈34% (35 .1% among men and 32 .6% 
among women) .
Rates of Death Attributable to CVD Have Declined, 
but the Burden of Disease Remains High
●● The 2009 overall rate of death attributable to CVD (Inter-
national Classification of Diseases, 10th Revision, codes 
I00–I99) was 236 .1 per 100 000 . The rates were 281 .4 per 
100 000 for white males, 387 .0 per 100 000 for black males, 
190 .4 per 100 000 for white females, and 267 .9 per 100 000 
for black females .
●● From 1999 to 2009, the relative rate of death attributable to 
CVD declined by 32 .7% . Yet in 2009, CVD (I00–I99; Q20–
Q28) still accounted for 32 .3% (787 931) of all 2 437 163 
deaths, or 1 of every 3 deaths in the United States .
●● On the basis of 2009 death rate data, >2150 Americans die 
of CVD each day, an average of 1 death every 40 seconds . 
About 153 000 Americans who died of CVD (I00–I99) in 
2009 were <65 years of age . In 2009, 34% of deaths attrib-
utable to CVD occurred before the age of 75 years, which is 
well before the average life expectancy of 78 .5 years .
●● Coronary heart disease alone caused ≈1 of every 6 deaths 
in the United States in 2009 . In 2009, 386 324 Americans 
died of coronary heart disease . Each year, an estimated 
≈635 000 Americans have a new coronary attack (defined 
as first hospitalized myocardial infarction or coronary heart 
disease death) and ≈280 000 have a recurrent attack . It is 
estimated that an additional 150 000 silent first myocardial 
infarctions occur each year . Approximately every 34 sec-
onds, 1 American has a coronary event, and approximately 
every 1 minute, an American will die of one .
●● From 1999 to 2009, the relative rate of stroke death fell by 
36 .9% and the actual number of stroke deaths declined by 
23 .0% . Yet each year, ≈795 000 people continue to experi-
ence a new or recurrent stroke (ischemic or hemorrhagic) . 
Approximately 610 000 of these are first attacks, and 
185 000 are recurrent attacks . In 20ss09, stroke caused ≈1 
of every 19 deaths in the United States . On average, every 
40 seconds, someone in the United States has a stroke and 
dies of one approximately every 4 minutes .
●● In 2009, 1 in 9 death certificates (274 601 deaths) in the United 
States mentioned heart failure . Heart failure was the underly-
ing cause in 56 410 of those deaths in 2009 . The number of 
any-mention deaths attributable to heart failure was approxi-
mately as high in 1995 (287 000) as it was in 2009 (275 000) . 
Additionally, hospital discharges for heart failure remained 
essentially unchanged from 2000 to 2010, with first-listed 
discharges of 1 008 000 and 1 023 000, respectively .
The 2013 Update Provides Critical Data About 
Cardiovascular Quality of Care, Procedure 
Utilization, and Costs
In light of the current national focus on healthcare utilization, 
costs, and quality, it is critical to monitor and understand the 
magnitude of healthcare delivery and costs, as well as the 
quality of healthcare delivery, related to CVD risk factors and 
conditions . The Statistical Update provides these critical data 
in several sections .
Quality-of-Care Metrics for CVDs
Quality data are available from the AHA’s “Get With The 
Guidelines” programs for coronary artery disease and heart 
failure and from the American Stroke Association/AHA’s 
“Get With The Guidelines” program for acute stroke . Similar 
data from the Veterans Healthcare Administration, national 
Medicare and Medicaid data, and Acute Coronary Treatment 
and Intervention Outcomes Network (ACTION)–“Get With 
The Guidelines” Registry data are also reviewed . These data 
show impressive adherence to guideline recommendations 
for many, but not all, metrics of quality of care for these 
hospitalized patients . Data are also reviewed on screening for 
CVD risk factor levels and control .
Cardiovascular Procedure Use and Costs
●● The total number of inpatient cardiovascular operations 
and procedures increased 28%, from 5 939 000 in 2000 to 
7 588 000 in 2010 (National Heart, Lung, and Blood Insti-
tute computation based on National Center for Health Sta-
tistics annual data) .
●● The total direct and indirect cost of CVD and stroke in the 
United States for 2009 is estimated to be $312 .6 billion . 
This figure includes health expenditures (direct costs, which 
include the cost of physicians and other professionals, hos-
pital services, prescribed medications, home health care, 
and other medical durables) and lost productivity that results 
from morbidity and premature mortality (indirect costs) .
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●● By comparison, in 2008, the estimated cost of all cancer 
and benign neoplasms was $228 billion ($93 billion in 
direct costs, $19 billion in morbidity indirect costs, and 
$116 billion in mortality indirect costs) . CVD costs more 
than any other diagnostic group .
The AHA, through its Statistics Committee, continuously 
monitors and evaluates sources of data on heart disease and 
stroke in the United States to provide the most current data 
available in the Statistics Update .
Finally, it must be noted that this annual Statistical Update 
is the product of an entire year’s worth of effort by dedicated 
professionals, volunteer physicians and scientists, and out-
standing AHA staff members, without whom publication of 
this valuable resource would be impossible . Their contribu-
tions are gratefully acknowledged .
Alan S. Go, MD
Melanie B. Turner, MPH
On behalf of the American Heart Association Statistics 
Committee and Stroke Statistics Subcommittee
Note: Population data used in the compilation of NHANES 
prevalence estimates are for the latest year of the NHANES 
survey being used . Extrapolations for NHANES prevalence 
estimates are based on the census resident population for 2010 
because this is the most recent year of NHANES data used in 
the Statistical Update .
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Table 1. Males and CVD: At-a-Glance Table
Diseases and Risk Factors Both Sexes Total Males White Males Black Males
Mexican  
American Males
Smoking
 Prevalence, 2011* 43.8 M (19.0%) 24.1 M (21.3%) 22.8% 23.3% 16.2%†
PA‡
 Prevalence, 2011* 21.0% 24.9% 26.2% 25.9% 19.0%†
Overweight and obesity
 Prevalence, 2010
  Overweight and obesity, BMI >25.0 kg/m2§ 154.7 M (68.2%) 79.9 M (72.9%) 73.1% 68.7% 81.3%
  Obesity, BMI >30.0 kg/m2§ 78.4 M (34.6%) 36.8 M (33.6%) 33.8% 37.9% 36.0%
Blood cholesterol
 Prevalence, 2010
  Total cholesterol >200 mg/dL§ 98.9 M (43.4%) 45.3 M (41.3%) 40.5% 38.6% 48.1%
  Total cholesterol >240 mg/dL§ 31.9 M (13.8%) 14.0 M (12.7%) 12.3% 10.8% 15.2%
  LDL cholesterol >130 mg/dL§ 71.0 M (31.1%) 35.2 M (31.9%) 30.1% 33.1% 39.9%
  HDL cholesterol <40 mg/dL§ 48.7 M (21.8%) 34.6 M (31.8%) 33.1% 20.3% 34.2%
HBP
 Prevalence, 2010§ 77.9 M (33.0%) 37.2 M (33.6%) 33.4% 42.6% 30.1%
 Mortality, 2009|| 61 762 27 668 20 286 6574 N/A
DM
 Prevalence, 2010
  Physician-diagnosed DM§ 19.7 M (8.3%) 9.6 M (8.7%) 7.7% 13.5% 11.4%
  Undiagnosed DM§ 8.2 M (3.5%) 5.3 M (4.7%) 4.5% 4.8% 6.6%
  Prediabetes§ 87.3 M (38.2%) 50.7 M (46.0%) 47.7% 35.7% 47.0%
  Incidence, diagnosed DM§ 1.9 M N/A N/A N/A N/A
 Mortality, 2009|| 68 705 35 054 28 205 5488 N/A
Total CVD
 Prevalence, 2010§ 83.6 M (35.3%) 40.7 M (36.7%) 36.6% 44.4% 33.4%
 Mortality, 2009|| 787 931 386 436 329 565 46 334 N/A
Stroke
 Prevalence, 2010§ 6.8 M (2.8%) 3.0 M (2.6%) 2.4% 4.3% 2.3%
 New and recurrent strokes|| 795.0 K 370.0 K 325.0 K 45.0 K N/A
 Mortality, 2009|| 128 842 52 073 43 190 6962 N/A
CHD
 Prevalence, CHD, 2010§ 15.4 M (6.4%) 8.8 M (7.9%) 8.2% 6.8% 6.7%
 Prevalence, MI, 2010§ 7.6 M (2.9%) 5.0 M (4.2%) 4.4% 3.9% 3.6%
 Prevalence, AP, 2010§ 7.8 M (3.2%) 3.7 M (3.3%) 3.3% 2.4% 3.4%
 New and recurrent CHD¶# 915.0 K 535.0 K 465.0 K 65.0 K N/A
 New and recurrent MI# 715.0 K 410.0 K N/A N/A N/A
 Incidence, AP (stable angina)** 500.0 K 320.0 K N/A N/A N/A
 Mortality, 2009, CHD|| 386 324 210 069 183 453 21 051 N/A
 Mortality, 2009, MI|| 125 464 68 814 60 316 6717 N/A
HF
 Prevalence, 2010§ 5.1 M (2.1%) 2.7 M (2.5%) 2.5% 4.1% 1.9%
 Mortality, 2009|| 56 410 23 563 20 815 2341 N/A
CVD indicates cardiovascular disease; M, millions; PA, physical activity; LDL, low-density lipoprotein; HDL, high-density lipoprotein; BMI, body mass index; HBP, 
high blood pressure; N/A, data not available; DM, diabetes mellitus; K, thousands; CHD, coronary heart disease (includes heart attack, angina pectoris chest pain, or 
both); MI, myocardial infarction (heart attack); AP, angina pectoris (chest pain); and HF, heart failure.
*Age ≥18 years (National Health Interview Survey).
†All Hispanic (National Health Interview Survey).
‡Met 2008 full Federal PA guidelines for adults.
§Age >20 years.
||All ages.
¶New and recurrent MI and fatal CHD.
#Age ≥35 years.
**Age ≥45 years.
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Table 2. Females and CVD: At-a-Glance Table
Diseases and Risk Factors Both Sexes Total Females White Females Black Females
Mexican American 
Females
Smoking
 Prevalence, 2011* 43.8 M (19.0%) 19.7 M (16.7%) 19.7% 15.1% 8.3%†
PA‡
 Prevalence, 2011* 21.0% 17.1% 20.0% 11.3% 11.5%†
Overweight and obesity
 Prevalence, 2010
  Overweight and obesity, BMI >25.0 kg/m2§ 154.7 M (68.2%) 74.8 M (63.7%) 60.2% 79.9% 78.2%
  Obesity, BMI >30.0 kg/m2§ 78.4 M (34.6%) 41.6 M (35.6%) 32.5% 53.9% 44.8%
Blood cholesterol
 Prevalence, 2010
  Total cholesterol >200 mg/dL§ 98.9 M (43.4%) 53.6 M (44.9%) 45.8% 40.7% 44.7%
  Total cholesterol >240 mg/dL§ 31.9 M (13.8%) 17.9 M (14.7%) 15.6% 11.7% 13.5%
  LDL cholesterol >130 mg/dL§ 71.0 M (31.1%) 35.8 M (30.0%) 29.3% 31.2% 30.4%
  HDL cholesterol <40 mg/dL§ 48.7 M (21.8%) 14.1 M (12.3%) 12.4% 10.2% 15.1%
HBP
 Prevalence, 2010§ 77.9 M (33.0%) 40.7 M (32.2%) 30.7% 47.0% 28.8%
 Mortality, 2009|| 61 762 34 094 26 201 6951 N/A
DM
 Prevalence, 2010
  Physician-diagnosed DM§ 19.7 M (8.3%) 10.1 M (7.9%) 6.2% 15.4% 12.0%
  Undiagnosed DM§ 8.2 M (3.5%) 2.9 M (2.3%) 1.8% 2.9% 4.7%
  Prediabetes§ 87.3 M (38.2%) 33.6 M (30.5%) 30.0% 29.0% 31.9%
  Incidence, diagnosed DM§ 1.9 M N/A N/A N/A N/A
 Mortality, 2009|| 68 705 33 651 25 908 6472 N/A
Total CVD
 Prevalence, 2010§ 83.6 M (35.3%) 42.9 M (34.0%) 32.4% 48.9% 30.7%
 Mortality, 2009|| 787 931 401 495 343 955 48 070 N/A
Stroke
 Prevalence, 2010§ 6.8 M (2.8%) 3.8 M (3.0%) 2.9% 4.7% 1.4%
 New and recurrent strokes|| 795.0 K 425.0 K 365.0 K 60.0 K N/A
 Mortality, 2009|| 128 842 76 769 65 574 8916 N/A
CHD
 Prevalence, CHD, 2010§ 15.4 M (6.4%) 6.6 M (5.1%) 4.6% 7.1% 5.3%
 Prevalence, MI, 2010§ 7.6 M (2.9%) 2.6 M (1.7%) 1.5% 2.3% 1.7%
 Prevalence, AP, 2010§ 7.8 M (3.2%) 4.1 M (3.2%) 2.8% 5.4% 3.3%
 New and recurrent CHD¶# 915.0 K 380.0 K 325.0 K 60.0 K N/A
 New and recurrent MI# 715.0 K 305.0 K N/A N/A N/A
 Incidence, AP (stable angina)** 500.0 K 180.0 K N/A N/A N/A
 Mortality, 2009, CHD|| 386 324 176 255 152 785 19 470 N/A
 Mortality, 2009, MI|| 125 464 56 650 48 802 6567 N/A
HF
 Prevalence, 2010§ 5.1 M (2.1%) 2.4 M (1.8%) 1.8% 3.0% 1.1%
 Mortality, 2009|| 56 410 32 847 29 372 2987 N/A
CVD indicates cardiovascular disease; M, millions; PA, physical activity; LDL, low-density lipoprotein; HDL, high-density lipoprotein; BMI, body mass index; HBP, 
high blood pressure; N/A, data not available; DM, diabetes mellitus; K, thousands; CHD, coronary heart disease (includes heart attack, angina pectoris chest pain, or 
both); MI, myocardial infarction (heart attack); AP, angina pectoris (chest pain); and HF, heart failure.
*Age >18 years (National Health Interview Survey).
†All Hispanic (National Health Interview Survey)
‡Met 2008 full Federal PA guidelines for adults.
§Age >20 years.
||All ages.
¶New and recurrent MI and fatal CHD.
#Age >35 years.
**Age >45 years.
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
Executive Summary: Heart Disease and Stroke Statistics—2013 Update  149
Table 3. Race/Ethnicity and CVD: At-a-Glance Table
Diseases and Risk Factors
Both  
Sexes
Whites Blacks
Mexican  
Americans
Hispanics/  
Latinos
Asians: 
Both 
Sexes
American Indian/
Alaska Native: 
Both SexesMales Females Males Females Males Females Males Females
Smoking
 Prevalence, 2011* 43.8 M (19.0%) 22.8% 19.7% 23.3% 15.1% 12.3% 16.2% 8.3% 9.6% 26.7%
PA†
 Prevalence, 2011* 21.0% 21.7% 17.8% 15.4% 15.4% 16.7% 17.0%
Overweight and obesity
 Prevalence, 2010
   Overweight and obesity, BMI 
>25.0 kg/m2‡
154.7 M (68.2%) 73.1% 60.2% 68.7% 79.9% 81.3% 78.2% N/A N/A N/A N/A
   Overweight and obesity, BMI 
>30.0 kg/m2‡
78.4 M (34.6%) 33.8% 32.5% 37.9% 53.9% 36.0% 44.8% N/A N/A N/A N/A
Blood cholestrol
 Prevalence, 2010
  Total cholesterol >200 mg/dL‡ 98.9 M (43.4%) 40.5% 45.8% 38.6% 40.7% 48.1% 44.7% N/A N/A N/A N/A
  Total cholesterol >240 mg/dL‡ 31.9 M (13.8%) 12.3% 15.6% 10.8% 11.7% 15.2% 13.5% N/A N/A N/A N/A
  LDL cholesterol >130 mg/dL‡ 71.0 M (31.1%) 30.1% 29.3% 33.1% 31.2% 39.9% 30.4% N/A N/A N/A N/A
  HDL cholesterol <40 mg/dL‡ 48.7 M (21.8%) 33.1% 12.4% 20.3% 10.2% 34.2% 15.1% N/A N/A N/A N/A
HBP
 Prevalence, 2010‡ 77.9 M (33.0%) 33.4% 30.7% 42.6% 47.0% 30.1% 28.8% 22.2%* 18.7* 25.8%*
 Mortality, 2009§ 61 762 20 286 26 201 6574 6951 N/A N/A N/A N/A N/A N/A
DM
 Prevalence, 2010
  Physician-diagnosed DM‡ 19.7 M (8.3%) 7.7% 6.2% 13.5% 15.4% 11.4% 12.0% N/A N/A N/A N/A
  Undiagnosed DM‡ 8.2 M (3.5%) 4.5% 1.8% 4.8% 2.9% 6.6% 4.7% N/A N/A N/A N/A
  Prediabetes‡ 87.3 M (38.2%) 47.7% 30.0% 35.7% 29.0% 47.0% 31.9% N/A N/A N/A N/A
  Incidence, diagnosed DM‡ 1.9 M N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
 Mortality, 2009§ 68 705 28 205 25 908 5488 6472 N/A N/A N/A N/A N/A N/A
Total CVD
 Prevalence, 2010‡ 83.6 M (35.3%) 36.6% 32.4% 44.4% 48.9% 33.4% 30.7% N/A N/A N/A N/A
  Mortality, 2009§ 787 931 329 565 343 955 46 334 48 070 N/A N/A N/A N/A N/A N/A
Stroke
 Prevalence, 2010‡ 6.8 M (2.8%) 2.4% 2.9% 4.3% 4.7% 2.3% 1.4% 2.8%* 2.7%* 4.6%||
 New and recurrent strokes§ 795.0 K 325.0 K 365.0 K 45.0 K 60.0 K N/A N/A N/A N/A N/A N/A
 Mortality, 2009§ 128 842 43 190 65 574 6962 8916 N/A N/A N/A N/A N/A N/A
CHD
 Prevalence, CHD, 2010‡ 15.4 M (6.4%) 8.2% 4.6% 6.8% 7.1% 6.7% 5.3% N/A N/A N/A N/A
 Prevalence, MI, 2010‡ 7.6 M (2.9%) 4.4% 1.5% 3.9% 2.3% 3.6% 1.7% N/A N/A N/A N/A
 Prevalence, AP, 2010‡ 7.8 M (3.2%) 3.3% 2.8% 2.4% 5.4% 3.4% 3.3% N/A N/A N/A N/A
 New and recurrent CHD¶# 915.0 K 465.0 K 325.0 K 65.0 K 60.0 K N/A N/A N/A N/A N/A N/A
 Mortality, CHD, 2009§ 386 324 183 453 152 785 21 051 19 470 N/A N/A N/A N/A N/A N/A
 Mortality, MI, 2009§ 125 464 60 316 48 802 6717 6567 N/A N/A N/A N/A N/A N/A
HF
 Prevalence, 2010‡ 5.1 M (2.1%) 2.5% 1.8% 4.1% 3.0% 1.9% 1.1% N/A N/A N/A N/A
 Mortality, 2009§ 56 410 20 815 29 372 2341 2987 N/A N/A N/A N/A N/A N/A
CVD indicates cardiovascular disease; M, millions; PA, physical activity; N/A, data not available; LDL, low-density lipoprotein; HDL, high-density lipoprotein; BMI, 
body mass index; HBP, high blood pressure; DM, diabetes mellitus; K, thousands; CHD, coronary heart disease (includes heart attack, angina pectoris chest pain, or 
both); MI, myocardial infarction (heart attack); AP, angina pectoris (chest pain); and HF, heart failure.
*Age >18 years (National Health Interview Survey).
†Met 2008 full Federal PA guidelines for adults.
‡Age >20 years.
§All ages.
||Figure not considered reliable.
¶New and recurrent MI and fatal CHD.
#Age >35 years.
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Table 4. Children, Youth, and CVD: At-a-Glance Table
NH Whites NH Blacks
Mexican  
Americans
Diseases and Risk Factors Both Sexes Total Males Total Females Males Females Males Females Males Females
Smoking, %
 High school students, grades 9–12
  Current cigarette smoking, 2011 18.1 19.9 16.1 21.5 18.9 13.7 7.4 19.5* 15.2*
  Current cigar smoking, 2011 13.1 17.8 8.0 19.0 7.5 15.1 8.5 17.2* 9.1*
PA†
 Prevalence, grades 9–12, 2011‡
 Met currently recommended levels of PA, % 49.5 59.9 38.5 62.1 42.6 57.1 31.9 57.1* 33.0*
Overweight and obesity
 Prevalence, 2010
   Children and adolescents, ages 2–19 y,  
overweight or obese
23.9 M (31.8%) 12.7 M (33.0%) 11.2 M (30.4%) 30.1% 25.6% 36.9% 41.3% 40.5% 38.2%
   Children and adolescents, age 2–19 y, 
obese‡
12.7 M (16.9%) 7.2 M (18.6%) 5.5 M (15.0%) 16.1% 11.7% 24.3% 24.3% 24.0% 18.2%
Blood cholesterol, mg/dL, 2010
 Mean total cholesterol
  Ages 4–11 y 161.9 162.3 161.5 160.9 161.6 165.2 157.9 159.6 160.7
  Ages 12–19 y 158.2 156.1 160.3 156.8 161.1 154.1 160.6 157.8 158.0
 Mean HDL cholesterol
  Ages 4–11 y 53.6 55.1 51.9 53.9 51.4 59.9 55.3 53.5 50.5
  Ages 12–19 y 51.4 49.2 53.6 48.4 53.0 53.9 55.4 47.5 53.3
 Mean LDL cholesterol
  Ages 12–19 y 89.5 88.6 90.5 90.4 90.9 85.8 91.8 90.6 87.1
Congenital cardiovascular defects
 Mortality, 2009§ 3189 1754 1435 1370 1086 304 268 N/A N/A
CVD indicates cardiovascular disease; NH, non-Hispanic; PA, physical activity; HDL, high-density lipoprotein; LDL, low-density lipoprotein; M, millions; and N/A, 
data not available. Overweight indicates a body mass index in the 95th percentile of the Centers for Disease Control and Prevention 2000 growth chart.
*Hispanic.
†Regular leisure-time PA.
‡Eaton DK, Kann L, Kinchen S, Shanklin S, Flint KH, Hawkins J, Harris WA, Lowry R, McManus T, Chyen D, Whittle L, Lim C, Wechsler H; Centers for Disease Con-
trol and Prevention. Youth risk behavior surveillance: United States, 2011. MMWR Surveill Summ. 2012;61:1–162.
§All ages.
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